Orforglipron plus insulin glargine improve glycemic control in type 2 diabetes

NEW ORLEANS —Adults with type 2 diabetes receiving once-daily orforglipron alongside insulin glargine had greater improvements in HbA1c than those receiving placebo, according to data from the ACHIEVE-5 trial. As Healio previously reported, the FDA approved orforglipron (Foundayo, Eli Lilly) in April for the treatment of overweight or obesity. The oral medication is also under development for the